



The TIMI Trials

ADDITIONAL PUBLICATIONS

1. Cannon CP, Braunwald E. GUSTO, TIMI and the case for rapid reperfusion. *Acta Cardiol* 1994;49:1-8.
2. Cannon CP, Braunwald E, McCabe CH, Antman EM, for the TIMI Investigators. The Thrombolysis in Myocardial Infarction (TIMI) Trials - the first decade. *J Intervent Cardiol* 1995;8:117-135.
3. Appleby MA, Angeja BG, Dauterman K, Gibson CM. Angiographic assessment of myocardial perfusion: TIMI myocardial perfusion (TMP) grading system. *Heart* 2001;86:485-6.
4. Llevadot J, Giugliano RP, Antman EM. Bolus fibrinolytic therapy in acute myocardial infarction. *JAMA* 2001;286:442-9.
5. Angeja BG, Gunda M, Murphy SA, Sobel BE, Rundle AC, Syed M, Asfour A, Borzak S, Gourlay SG, Barron HV, Gibbons RJ, Gibson CM. TIMI myocardial perfusion grade and ST segment resolution: association with infarct size as assessed by single photon emission computed tomography imaging. *Circulation* 2002;105:282-5.
6. Angeja BG, Kermgard S, Chen MS, McKay M, Murphy SA, Antman EM, Cannon CP, Braunwald E, Gibson CM. The Smoker's Paradox: Insights from the angiographic substudies of the TIMI trials. *J Thromb Thrombolysis* 2002;13:133-9.
7. Murphy SA, Chen C, Cannon CP, Antman EM, Gibson CM. Impact of gender on angiographic and clinical outcomes after fibrinolytic therapy in acute MI. *Am J Cardiol* 2002;90:766-770.
8. Shields DC, Fitzgerald AP, O'Neill PA, Muckian C, Kenny D, Moran B, Cannon CP, Byrne CE, Fitzgerald DJ. The contribution of genetic factors to thrombotic and bleeding outcomes in coronary patients randomised to IIb/IIIa antagonists. *Pharmacogenomics J*. 2002;2:182-90.
9. Kloner RA, Poole K, Shook T, Przyklenk K, Perritt K, Cannon CP. Comparison of acute myocardial infarct size in patients $>$ or $=65$ years versus $<$ 65 years in the prethrombolytic period versus the thrombolytic period. *Am J Cardiol* 2002;89:1291-3.
10. Gibson CM, de Lemos JA, Murphy SA, Marble SJ, Antman EM, Cannon CP. Methodologic and Clinical Validation of the TIMI Myocardial Perfusion Grade in Acute MI. *J Thromb Thrombolysis*. 2002;14:233-7.
11. Gibson CM, Cannon CP, Murphy SA, Marble SJ, Barron HV, Braunwald E for the TIMI Study Group. Relationship of the TIMI Myocardial Perfusion Grades, TIMI Flow Grades and TIMI Frame Count to Long Term Outcomes Following Thrombolytic Administration. *Circulation* 2002;105:1909-1913.
12. Angeja BG, de Lemos J, Murphy SA, Marble SJ, Antman EM, Cannon CP, Braunwald E, Gibson CM for the TIMI Study Group. Impact of diabetes mellitus on epicardial and microvascular flow after fibrinolytic therapy. *Am Heart J* 2002;144:649-656.
13. Gibson CM, Karha J, James D, Murphy SA, James D, Morrow DA, Cannon CP, Giugliano RP, Antman EM, Braunwald E. Early and long term clinical outcomes associated with reinfarction following fibrinolytic administration in the Thrombolysis in Myocardial Infarction trials. *J Am Coll Cardiol* 2003;42:7-16.
14. Wong GC, Murphy SA, Wiviott SD, Giugliano RP, Antman EM, Marble SJ, Dumaine R, McCabe CH, Gibson CM. Statin therapy within 2 weeks prior to admission is associated with improved myocardial perfusion in ST elevation myocardial infarction: a TIMI angiographic substudy. *Circulation* 2003;108:1686.
15. Karha J, Murphy SA, Kirtane AJ, DeLemos JA, Aroesty JM, Cannon CP, Antman EM, Braunwald E, Gibson CM. Evaluation of the association of proximal coronary culprit artery lesion location with clinical outcomes in acute myocardial infarction. *Am J Cardiol* 2003;92:913-918.
16. Gibson CM, Pinto DS, Murphy SA, Morrow DA, Hobbach H-P, Wiviott SD, Giugliano RP, Cannon CP, Antman EM, Braunwald E. Association of creatinine and creatinine clearance on presentation in acute myocardial infarction with subsequent mortality. *J Am Coll Cardiol* 2003;42:1535-1543.
17. Gibson CM, Gibson WJ, Murphy SA, Marble SJ, McCabe CH, Turakhia MP, Kirtane AJ, Karha J, Aroesty JM, Giugliano RP, Antman EM, for the TIMI Study Group. Association of the Fibonacci Cascade with the distribution of coronary artery lesions responsible for ST-segment elevation myocardial infarction. *Am J Cardiol* 2003;92:595-597.

18. Gibson CM, Kirtane AJ, Murphy SA, Karha J, Cannon CP, Giugliano RP, Roe MT, Harrington RA, Ohman EM, Antman EM. Distance From the Coronary Ostium to the Culprit Lesion in Acute ST-Elevation Myocardial Infarction and its Implications Regarding The Potential Prevention of Proximal Plaque Rupture. *J Thromb Thrombolysis* 2003;15:189-96.
19. Gibson CM, Karha J, Murphy SA, de Lemos JA, Morrow DA, Giugliano RP, Roe MT, Harrington RA, Cannon CP, Antman EM, Califf RM, Braunwald E. Association of a pulsatile blood flow pattern on coronary arteriography and short-term clinical outcomes in acute myocardial infarction. *J Am Coll Cardiol* 2004;43:1170-1176.
20. Giugliano RP, Sabatine S, Gibson CM, Roe MT, Harrington RA, Murphy SA, Morrow DA, Antman EM, Braunwald E. Combined assessment of Thrombolysis in Myocardial Infarction flow grade, myocardial perfusion grade, and ST-segment resolution to evaluate epicardial and myocardial reperfusion. *Am J Cardiol* 2004;93:1362-1367.
21. Morrow DA, Antman EM, Murphy SA, Assmann SF, Giugliano RP, Cannon CP, Gibson CM, McCabe CH, Barron HV, van de Werf F, Braunwald E. The Risk Score Profile: A novel approach to characterizing the risk of populations enrolled in clinical studies. *Eur Heart J* 2004;25:1139-1145.
22. Gardner GS, Frisch DR, Murphy SA, Kirtane AJ, Giugliano RP, Antman EM, Braunwald E, Gibson CM for the TIMI Study Group. Effect of rescue or adjunctive percutaneous coronary intervention of the culprit artery after fibrinolytic administration on epicardial flow in nonculprit arteries. *Am J Cardiol* 2004;94:178-80.
23. Gibson CM, Murphy SA, Morrow DA, Aroesty JJM, Gibbons RJ, Gourlay SG, Barron HV, Giugliano RP, Antman EM, Braunwald E. Angiographic perfusion score. An angiographic variable that integrates both epicardial and tissue level perfusion before and after facilitated percutaneous coronary intervention in acute myocardial infarction. *Am Heart J* 2004;148:336-40.
24. Bavry AA, Kumbhani DJ, Quiroz R, Ramchandani SR, Kenchaiah S, Antman EM. Invasive therapy along with glycoprotein IIb/IIIa inhibitors and intracoronary stents improves survival in non-ST-segment elevation acute coronary syndromes: a meta-analysis and review of the literature. *Am J Cardiol* 2004;93:830-5.
25. Kashani A, Giugliano RP, Antman EM, Morrow DA, Gibson CM, Murphy SA, Braunwald E. Severity of heart failure, treatments and outcomes after fibrinolysis in patients with ST-elevation myocardial infarction. *Eur Heart J* 2004;25:1702-10.
26. Gibson CM, Singh KP, Murphy SA, DiBattiste PM, Demopoulos LA, Cannon CP, Braunwald E; TIMI Study Group. Association between duration of tirofiban therapy before percutaneous intervention and tissue level perfusion (a TACTICS-TIMI 18 substudy). *Am J Cardiol* 2004;94:492-4.
27. Gibson CM, Bigelow B, James D, Tepper MR, Murphy SA, Kirtane AJ, Giugliano RP, Cannon CP, Antman EM. Association of lesion complexity following fibrinolytic administration with mortality in ST-elevation myocardial infarction. *Am J Cardiol* 2004;94:108-11.
28. Gibson CM, Murphy S, Kirtane AJ, Giugliano R, Cannon CP, Antman E, Braunwald E. Association of Duration of Symptoms at Presentation with Angiographic and Clinical Outcomes Following Fibrinolytic Therapy. *J Am Coll Cardiol* 2004;44:980-7.
29. Sadanandan S, Cannon CP, Cheuri K, Murphy S, DiBattiste P, Morrow D, De Lemos J, Eugene B, Gibson CM. Association of elevated B-type natriuretic peptide levels with angiographic findings among patients with unstable angina and non-ST elevation myocardial infarction. *J Am Coll Cardiol* 2004;44:564-8.
30. Sadanandan S, Cannon CP, Gibson CM, Desai R, Murphy S, DiBattiste P, Braunwald E. A risk score for predicting coronary artery bypass surgery in patients with non-ST elevation acute coronary syndromes. *J Am Coll Cardiol* 2004;44:799-803.
31. Kirtane AJ, Bui A, Murphy S, Karmaliotis D, Rahman A, Aroesty JM, Giugliano R, Cannon CP, Antman EM, Gibson CM. Association of Epicardial and Tissue-level Reperfusion with Left Ventricular End-Diastolic Pressures in ST-Elevation Myocardial Infarction. *J Thromb Thrombolysis* 2004;17:177-84.
32. Gibson CM, Dumaine RL, Gelfand EV, Murphy SA, Morrow DA, Wiviott SD, Giugliano RP, Cannon CP, Antman EM, Braunwald E for the TIMI Study Group. Association of glomerular filtration rate on presentation with subsequent mortality in non-ST-segment elevation acute coronary syndrome: Observations in 13,307 patients in five TIMI trials. *Eur Heart J* 2004;25:1998-2005.
33. Turakhia MP, Murphy SA, Pinto TL, Antman EM, Giugliano RP, Cannon CP, Braunwald E, Gibson CM for the Thrombolysis in Myocardial Infarction Study Group. Association of platelet count with residual thrombus in the myocardial infarct-related coronary artery among patients treated with fibrinolytic

34. Karmaliotis D, Turakhia MP, Kirtane AJ, Murphy SA, Kosmidou I, Morrow DA, Giugliano RP, Cannon CP, Antman EM, Braunwald E, Gibson CM for the TIMI Study Group. Sequential risk stratification using TIMI risk score and TIMI flow grade among patients treated with fibrinolytic therapy for ST-segment elevation acute myocardial infarction. *Am J Cardiol* 2004;94:1113-7.
35. Deo R, Khera A, McGuire DK, Murphy SA, Meo Neto JP, Morrow DA, de Lemos JA. Association Between Plasma Levels of Monocyte Chemoattractant Protein-1, Traditional Cardiovascular Risk Factors and Subclinical Atherosclerosis. *J Am Coll Cardiol* 2004; 44: 1812-8.
36. Morrow DA, Sabatine MS, Antman EM, Cannon CP, Braunwald E, Theroux P. Usefulness of tirofiban among patients treated without percutaneous coronary intervention (TIMI high risk patients in PRISM-PLUS). *Am J Cardiol* 2004;94:774-6.
37. Kirtane A, Barron HV, Murphy SA, Gibson CM. Association of absolute neutrophil count with patency in AMI. *Am J Cardiol* 2004;93:532-6.
38. Kirtane AJ, Bui A, Murphy SA, Barron HV, Gibson CM. Association of peripheral neutrophilia with adverse angiographic outcomes in ST-elevation myocardial infarction. *Curr Treat Options Cardiovasc Med* 2004;6:69-77.
39. Karha J, Gibson CM, Murphy SA, Dibattiste PM, Cannon CP; TIMI Study Group. Safety of stress testing during the evolution of unstable angina pectoris or non-ST-elevation myocardial infarction. *Am J Cardiol* 2004;94:1537-9.
40. Wiviott SD, Morrow DA, Frederick PD, Giugliano RP, Gibson CM, McCabe CH, Cannon CP, Antman EM, Braunwald E. Performance of the Thrombolysis in Myocardial Infarction risk index in the National Registry of Myocardial Infarction -3 and -4: A simple index that predicts mortality in ST-segment elevation myocardial infarction. *J Am Coll Cardiol* 2004;44:783-9.
41. Gibson CM, Murphy SA, Kirtane AJ, Giugliano RP, Cannon CP, Antman EM, Braunwald E for the TIMI Study Group. Association of duration of symptoms at presentation with angiographic and clinical outcomes after fibrinolytic therapy in patients with ST-segment elevation myocardial infarction. *J Am Coll Cardiol* 2004;44:980-7.
42. Kirtane AJ, Weisbord A, Karmaliotis D, Murphy SA, Giugliano RP, Cannon CP, Antman EM, Ohman EM, Roe MT, Braunwald E, Gibson CM for the TIMI Study Group. Relation of impaired Thrombolysis in Myocardial Infarction myocardial perfusion grades to residual thrombus following the restoration of epicardial patency in ST-elevation myocardial infarction. *Am J Cardiol* 2005;95:224-7.
43. Kirtane AJ, Kosmidou I, Karmaliotis D, Murphy SA, Giugliano RP, Cannon CP, Antman EM, Braunwald E, Gibson CM. Association of culprit lesion calcium with angiographic and clinical outcomes in patients with ST-elevation myocardial infarction treated with fibrinolytic therapy. *Am J Cardiol* 2005;95:337-42.
44. Gibson CM, Kirtane AJ, Boundy K, Ly H, Karmaliotis D, Murphy SA, Giugliano RP, Cannon CP, Antman EM, Braunwald E. Association of a negative residual stenosis following rescue/adjunctive percutaneous coronary intervention with impaired myocardial perfusion and adverse outcomes among ST-segment elevation myocardial infarction patients. *J Am Coll Cardiol* 2005;45:357-62.
45. Sabatine MS, Morrow DA, Giugliano RP, Burton PBJ, Murphy SA, McCabe CH, Gibson CM, Braunwald E. Association of hemoglobin levels with clinical outcomes in acute coronary syndromes. *Circulation* 2005; 111:2042-9.
46. Ilkhanoff L, O'Donnell CJ, Camargo CA, O'Halloran TD, Giugliano RP, Lloyd-Jones DM. Usefulness of the TIMI Risk Index in predicting short- and long-term mortality in patients with acute coronary syndromes. *Am J Cardiol* 2005;96:773-7.
47. Mega JL, Morrow DA, Sabatine MS, Zhao X-Q, Snapinn SM, DiBattiste PM, Gibson CM, Antman EM, Braunwald E, Theroux P. Correlation between the TIMI risk score and high-risk angiographic findings in non-ST elevation acute coronary syndromes: Observations from the Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) trial. *Am Heart J* 2005;149:846-50.
48. Kashani A, Gibson CM, Murphy SA, Sabatine MS, Morrow DA, Antman EM, Giugliano RP. Angiography and revascularization in patients with heart failure following fibrinolytic therapy for ST-elevation acute myocardial infarction. *Am J Cardiol* 2005;95:228-33.
49. Pinto DS, Skolnick AH, Kirtane AJ, Murphy SA, Barron HV, Giugliano RP, Cannon CP, Braunwald E, Gibson CM. U-shaped relationship of blood glucose with adverse outcomes among patients with ST-segment elevation myocardial infarction. *J Am Coll Cardiol* 2005;46:178-80.
50. Ly HQ, Kirtane AJ, Buros J, Giugliano RP, Popma JJ, Antman EM, Harrington RA, Ohman EM, Gibson

51. Kirtane AJ, Martinezclark P, Rahman AM, Ray KK, Karpaliotis D, Murphy SA, Giugliano RP, Cannon CP, Antman EM, Roe MT, Harrington RA, Ohman EM, Braunwald E, Gibson CM. Association of smoking with improved myocardial perfusion and the angiographic characterization of myocardial tissue perfusion after fibrinolytic therapy for ST-segment elevation myocardial infarction. *J Am Coll Cardiol* 2005;45:321-3.
52. Kirtane AJ, Leder DM, Waikar SS, Chertow GM, Ray KK, Pinto DS, Karpaliotis D, Burger AJ, Murphy SA, Cannon CP, Braunwald E, Gibson CM. Serum blood urea nitrogen as an independent marker of subsequent mortality among patients with acute coronary syndromes and normal to mildly reduced glomerular filtration rates. *J Am Coll Cardiol* 2005;45:1781-6.
53. Pinto DS, Skolnick AH, Kirtane AJ, Murphy SA, Barron HV, Giugliano RP, Cannon CP, Braunwald E, Gibson CM. U-shaped relationship of blood glucose with adverse outcomes among patients with ST-segment elevation myocardial infarction. *J Am Coll Cardiol* 2005;46:178-80.
54. Januzzi JL, Newby LK, Murphy SA, Pieper K, Antman EM, Morrow DA, Sabatine MS, Ohman EM, Cannon CP, Braunwald E. Predicting a late positive serum troponin in initially troponin-negative patients with non-ST-elevation acute coronary syndrome: Clinical predictors and validated risk score results from the TIMI IIIB and GUSTO IIA studies. *Am Heart J* 2006;151:360-6.
55. Ahmed S, Antman EM, Murphy SA, Giugliano RP, Cannon CP, White H, Morrow DA, Braunwald E. Poor outcomes after fibrinolytic therapy for ST-segment elevation myocardial infarction: Impact of age (a metaanalysis of a decade of trials). *J Thromb Thrombolysis* 2006;21:119-29.
56. Wiviott SD, Morrow DA, Frederick PD, Antman EM, Braunwald E. Application of the Thrombolysis in Myocardial Infarction risk index in non-ST-segment elevation myocardial infarction evaluation of patients in the National Registry of Myocardial Infarction. *J Am Coll Cardiol* 2006;47:1553-8.
57. Dumaine R, Gibson CM, Murphy SA, Ly HQ, McCabe CH, Giugliano RP, Cannon CP, Antman EM, Braunwald E. Association of a history of systemic hypertension with mortality, thrombotic, and bleeding complications following non ST-segment elevation acute coronary syndrome. *J Clin Hypertens* 2006;8:315-22.
58. Ly Q, Kirtane AJ, Murphy SA, Buros J, Cannon CP, Braunwald E, Gibson CM. Association of platelet counts on presentation and clinical outcomes in ST elevation myocardial infarction (From the TIMI trials). *Am J Cardiol* 2006;98:1-5.
59. Deibele AJ, Kirtane AJ, Pinto DS, Lucca MJ, Neva C, Shui A, Murphy SA, Tchong JE, Gibson CM. Intracoronary bolus administration of eptifibatide during percutaneous coronary stenting for non ST elevation myocardial infarction and unstable angina. *J Thromb Thrombolysis* 2006;22:47-50.
60. Cannon CP, Steinberg BA, Murphy SA, Mega JL, Braunwald E. Meta-analysis of cardiovascular outcomes trials comparing intensive versus moderate statin therapy. *J Am Coll Cardiol* 2006;48:438-45.
61. Wiviott SD, Morrow DA, Frederick PD, Antman EM, Braunwald E, Application of the Thrombolysis in Myocardial Infarction risk index in non-ST-segment elevation myocardial infarction: evaluation of patients in the National Registry of Myocardial Infarction. *J Am Coll Cardiol* 2006;47:1553-8.
62. Wiviott SD, de Lemos JA, Cannon CP, Blazing M, Murphy SA, McCabe CH, Califf R, Braunwald E. A tale of two trials: A comparison of the post-ACS lipid lowering trials A to Z and PROVE IT-TIMI 22. *Circulation* 2006;113:1406-14.
63. Pride YB, Buros JL, Lord E, Southard MC, Harrigan CJ, Ciaglo LN, Sabatine MS, Cannon CP, Gibson CM. Angiographic perfusion score in patients treated with PCI at late angiography following fibrinolytic administration for ST-segment elevation myocardial infarction is associated with morbidity and mortality at 30 days. *J Thromb Thrombolysis* 2007;in press.
64. Donahoe SM, Stewart GC, McCabe, CH, Mohanavelu S, Murphy SA, Cannon CP, Antman EM. Diabetes and mortality following acute coronary syndromes. *JAMA* 2007;298:765-75.
65. Murphy SA, Cannon CP, Wiviott SD, de Lemos JA, Blazing MA, McCabe CH, Califf RM, Braunwald E. Effect of intensive lipid-lowering therapy on mortality after acute coronary syndrome (a patient-level analysis of the Aggrastat to Zocor and Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 trials). *Am J Cardiol* 2007;100:1047-51.
66. Sabatine MS, Morrow DA, Jablonski KA, Rice MM, Warnica JW, Domanski MJ, Hsia J, Gersh BJ, Rifai N, Ridker PM, Pfeffer MA, Braunwald E. Prognostic significance of the Centers for Disease Control/American Heart Association high-sensitivity C-reactive protein cut points for cardiovascular and

67. Brilakis ES, de Lemos JA, Cannon CP, Wiviott SD, Murphy SA, Morrow DA, Sabatine MS, Banerjee S, Blazing MA, Califf RM, Braunwald E. Outcomes of patients with acute coronary syndrome and previous coronary artery bypass grafting (from the Pravastatin or Atorvastatin Evaluation and Infection Therapy [PROVE IT-TIMI 22] and the Aggrastat to Zocor [A to Z] Trials.) *Am J Cardiol* 2008;102:552-8.
68. McLean DS, Ravid S, Blazing M, Gersh B, Shui A, Cannon CP. Effect of statin dose on incidence of atrial fibrillation: data from the Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 (PROVE IT-TIMI 22) and Aggrastat to Zocor (A to Z) trials. *Am Heart J* 2008;155:298-302.
69. O'Donoghue M, Boden WE, Braunwald E, Cannon CP, Clayton TC, de Winter RJ, Fox KAA, Lagerqvist B, McCullough PA, Murphy SA, Spacek R, Swahn E, Wallentin L, Windhausen F, Sabatine MS. Early invasive vs. conservative treatment strategies in women and men with unstable angina and non-ST-segment elevation myocardial infarction: a meta-analysis. *JAMA* 2008;300:71-80.